Drug-drug interactions and drug resistance will limit access to treatment in patients with HIV and hepatitis C virus coinfection

摘要

To the Editor-Hulskotte and colleagues report significant pharmacokinetic interactions between the hepatitis C protease inhibitor (PI) boceprevir and protease inhibitors used in the treatment of human immunodeficiency virus (HIV) [l].Coin-fection with hepatitis C virus (HCV) and HIV is a common clinical problem [2]. Boceprevir has been shown to significantly improve outcomes in patients with genotype 1 HCV infection as compared to standard therapy [3], but drug-drug interactions may significantly limit access to these agents in coinfected patients.